Lilly shares fall midday on lower fourth quarter revenue guidance
The company expects fourth-quarter revenue to be about $13.5 billion.
Eli Lilly and Co.
-
State’s big, bold LEAP District play draws some reflection
The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic leaders say the project is a huge success, but some political leaders are cautious.
Read More -
Roche data shows simple blood test can help determine if someone has Alzheimer’s
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and Drug Administration granted a breakthrough device designation to the product.
Read More -
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
Read More -
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
Read More
Articles
Lilly sees new weight-loss pill approval in early 2026, CEO says
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
Medicaid coverage of weight-loss drugs could cost state up to $70 million a year
The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.
2024 Newsmaker: Lilly CEO David Ricks
Ricks—IBJ’s newsmaker of the year in 2023—returns to the newsmaker list in 2024 after a year that included a stock price that skyrocketed to an all-time high of $972 and announcements about big new investments in Lebanon and Ireland.
2024 Year in Review: Lilly’s total investment at LEAP climbs to $13.5B
Lilly said the expansion is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.
LEAP district developments among year’s top tech stories
The ongoing progress to develop the planned LEAP Innovation and Research District, a 9,000-acre tech park in Boone County, was among the top local tech stories of 2024.
Lilly stock caught up in wave of uncertainty
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
Lilly’s U.S. weight-loss drug shortage ends, curtailing copycats
The FDA had previously said Lilly’s drugs were out of shortage and that making copies must cease in October. Compounders sued, causing the FDA to pause enforcement while it reevaluated its decision.
State approves $60M for LEAP District development for Lilly, Meta projects
The state will eventually recoup much of that investment when LEAP land is sold to tenants, officials from the Indiana Economic Development Corp. said.
IEDC requests additional $60M for Lilly, Meta land, infrastructure at LEAP
The state’s job-creation agency is seeking $27 million to purchase about 307 acres and pay for deposits and option payments for additional land west of Interstate 65. Another $33 million is being sought for infrastructure work.
Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025
David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most popular drug in the 148-year-old company’s history.
Lilly to test obesity drugs for addiction treatment, CEO says
Lilly also approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled by Zepbound and Mounjaro.
Lilly to spend $3B to expand Wisconsin factory
Under pressure to keep up with soaring demand for drug treatments for obesity, diabetes and other diseases, Eli Lilly and Co. is planning its single largest U.S. manufacturing investment outside of Indiana.
UIndy lands $5M gift from graduate and retired Lilly exec Stephen Fry
The money will go to start three programs designed to give students real-world business experience along with their classroom experience.
Lilly expands research in Singapore with focus on sleep quality
Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and development in the city-state.
Lilly CEO Dave Ricks named Watanabe Award winner
Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care innovation.
UPDATE: Lilly shares tumble on earnings report that falls short of Wall Street expectations
The Indianapolis-based drugmaker missed expectations on sales of two popular drugs, diabetes treatment Mounjaro and weight-loss treatment Zepbound, which it attributed to inventory decreases in the wholesaler channel.
UK regulator approves Lilly’s new Alzheimer’s drug but government won’t pay for it
Britian’s National Institute for Health and Care Excellence said more evidence was needed to prove Kisunla’s worth. Lilly says a year’s worth of treatment is $32,000.
Amid backlash, FDA changes course over shortage of Lilly weight-loss drugs
The U.S. Food and Drug Administration said it would not take enforcement action—for now—against pharmacies making their own versions of weight-loss drugs based on Eli Lilly’s tirzepatide.
Alzheimer’s patients and their families hear a new word: Progress
Two new drugs—including one from Indianapolis-based Eli Lilly—and better detection methods offer promise for people dealing with the disease.